8
Oct
2024

Medsyn (Chengdu) Biotechnology Co., Ltd

Exhibitor at CPHI Milan 2024 stand 4G21, API
About Us

Medsyn Biotechnology Co., Ltd. is a biopharmaceutical company driven by research and innovation. Company's core business is to provide Small-molecule Intermediates,API techpack,PROTAC E3 and linkers.Company has two R&D centers with UPLC-MS,UPLC,HPLCs and 3 Doctors, 8 Masters.We also have two manufacturer sites in China which can ensure the stable supply from grams to tons.The main indications we are focus are Weight loss and Type 2 diabetes,Anti-cancer,Antithrombosis,Sedative.

Read more Show less
Categories
more categories Show less
  • CN
  • 2023
    On CPHI since
View company profile
Contact info
  • 86-15121117545
  • 5th Floor.Block B., No.5.South Keyuan Rd., 610093, Chengdu, Sichuan, China
Show contact info Hide contact info
Event information
CPHI Milan 2024
  • 08 Oct 2024 - 10 Oct 2024
  • Fiera Milano, Italy
  • Visit us at stand 4G21, API

Products Featured at CPHI Milan 2024

  • Bavdegalutamide

    Product Bavdegalutamide

     Given these mechanisms of resistance, our goal is to eliminate the AR protein using the PROteolysis TArgeting Chimera (PROTAC) technology. Here we report an orally bioavailable small molecule ARV-110 that leads to ubiquitination and degradation of AR. ARV-110 completely degrades AR in all cell lines ...
  • Milvexian

    Product Milvexian

    Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.In this parallel-group, p...
  • Orforglipron

    Product Orforglipron

    Obesity is a major risk factor for many leading causes of illness and death worldwide. Data are needed regarding the efficacy and safety of the nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron as a once-daily oral therapy for weight reduction in adults with obesity.In this phase 2, ...
  • Pirtobrutinib

    Product Pirtobrutinib

    Pirtobrutinib, a highly selective kinase inhibitor, utilizes a novel binding mechanism and is the first and only FDA approved non-covalent (reversible) BTK inhibitor. Jaypirca can reestablish BTK inhibition in MCL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanub...
  • posaconazole

    Product posaconazole

    Posaconazole is a broad-spectrum, second generation, triazole compound with antifungal activity.The antifungal drug posaconazole, have potent trypanocidal activity.  Posaconazole exhibited potent antifungal activity against a wide variety of clinically important fungal pathogens and was...